{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:36:48Z","timestamp":1773387408623,"version":"3.50.1"},"reference-count":27,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bausch Health US, LLC"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2021,10,23]]},"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To describe patient characteristics and healthcare costs associated with uveitic macular oedema (UME) in US clinical practices from a commercial payer\u2019s perspective.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>The IBM MarketScan Commercial Subset (1 October 2015\u201331 March 2020) was used to identify patients with non-infectious uveitis (NIU), with or without UME. Patients with UME at any time were further classified into subgroups of patients who received a UME diagnosis during the study period and those who received a UME diagnosis and local steroid injection (LSI) during the study period. Demographic and clinical characteristics, NIU-related treatments and healthcare costs were described for each cohort and subgroup during the most recent 12 months of continuous health plan enrolment. Healthcare costs were also described by vision status among all patients with NIU.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 36\u2009322 patients with NIU were identified, of whom 3 301 (9.1%) had UME and 33\u2009021 (90.9%) had no UME. Patients with UME more frequently received NIU-related treatment compared with those without UME (64.6% vs 45.0%), particularly LSI treatment (12.5% vs 0.7%). Mean total all-cause healthcare costs per-patient-per-year (PPPY) were higher among patients with UME ($19 851) than patients without UME ($16 188) and were especially high among those with bilateral UME ($24 162). Further, vision loss was more commonly observed in those with UME versus those without UME (5.7% vs 2.2%) and a trend of increasing healthcare costs with increasing vision loss was observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>NIU is associated with substantial clinical and economic burden, particularly when UME is present.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjophth-2021-000896","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T11:50:08Z","timestamp":1636545008000},"page":"e000896","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer\u2019s perspective"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0985-9551","authenticated-orcid":false,"given":"Seenu M","family":"Hariprasad","sequence":"first","affiliation":[{"name":"Ophthalmology and Visual Science, University of Chicago, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Joseph","sequence":"additional","affiliation":[{"name":"Bausch Health US, LLC, Bridgewater, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Gagnon-Sanschagrin","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2832-5355","authenticated-orcid":false,"given":"Elizabeth","family":"Serra","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3214-6181","authenticated-orcid":false,"given":"Subrata","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Real World Evidence, PharmaQuant, Kolkata, West Bengal, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"B\u00e9dard","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Gu\u00e9rin","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas Arno","family":"Albini","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute, Miami, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"2025090110051491000_6.1.e000896.1","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","article-title":"Prevalence of noninfectious uveitis in the United States: a Claims-Based analysis","volume":"134","author":"Thorne","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"2025090110051491000_6.1.e000896.2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2147\/OPTH.S180580","article-title":"Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges","volume":"13","author":"Massa","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"2025090110051491000_6.1.e000896.3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.semarthrit.2019.06.004","article-title":"New observations and emerging ideas in diagnosis and management of non-infectious uveitis: a review","volume":"49","author":"Rosenbaum","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2025090110051491000_6.1.e000896.4","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/eye.2016.115","article-title":"Uveitic macular edema","volume":"30","author":"Fardeau","year":"2016","journal-title":"Eye"},{"key":"2025090110051491000_6.1.e000896.5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/09273948.2019.1576910","article-title":"Epidemiology of macular edema in uveitis","volume":"27","author":"Accorinti","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"2025090110051491000_6.1.e000896.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.03.027"},{"key":"2025090110051491000_6.1.e000896.7","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12987"},{"key":"2025090110051491000_6.1.e000896.8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3109\/09273948.2016.1139734","article-title":"Visual functioning and health-related quality-of-life are compromised in patients with uveitis","volume":"25","author":"Hui","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"2025090110051491000_6.1.e000896.9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/09273948.2017.1285034","article-title":"Vision-related quality of life in patients with non-infectious uveitis: a cross-sectional study","volume":"26","author":"Arriola-Villalobos","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"2025090110051491000_6.1.e000896.10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4155\/cli.15.1","article-title":"Uveitic macular edema: a stepladder treatment paradigm","volume":"5","author":"Preble","year":"2015","journal-title":"Clin Investig"},{"key":"2025090110051491000_6.1.e000896.11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2147\/DDDT.S166092","article-title":"Update in treatment of uveitic macular edema","volume":"13","author":"Koronis","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"2025090110051491000_6.1.e000896.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.07.054"},{"key":"2025090110051491000_6.1.e000896.13","unstructured":"Bureau of Labor Statistics . Consumer price index 2020. Available: https:\/\/www.bls.gov\/cpi\/tables\/supplemental-files\/home.htm"},{"key":"2025090110051491000_6.1.e000896.14","doi-asserted-by":"crossref","DOI":"10.1186\/1869-5760-3-64","article-title":"Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA","volume":"3","author":"Chu","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"2025090110051491000_6.1.e000896.15","article-title":"The economic burden of diabetic macular edema from a US. private payer perspective","volume":"52","author":"Lanzetta","year":"2011","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2025090110051491000_6.1.e000896.16","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.126.12.1748"},{"key":"2025090110051491000_6.1.e000896.17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1185\/03007990903439046","article-title":"Resource use and costs of branch and central retinal vein occlusion in the elderly","volume":"26","author":"Fekrat","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"2025090110051491000_6.1.e000896.18","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1097\/IAE.0000000000000217","article-title":"Direct medical costs and resource use for treating central and branch retinal vein occlusion in commercially insured working-age and Medicare populations","volume":"34","author":"Su\u00f1er","year":"2014","journal-title":"Retina"},{"key":"2025090110051491000_6.1.e000896.19","first-page":"37","article-title":"Resource utilization and costs of age-related macular degeneration","volume":"27","author":"Halpern","year":"2006","journal-title":"Health Care Financ Rev"},{"key":"2025090110051491000_6.1.e000896.20","doi-asserted-by":"publisher","DOI":"10.1080\/09286580601139212"},{"key":"2025090110051491000_6.1.e000896.21","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1007\/s11136-019-02260-3","article-title":"Low vision status and declining vision decrease health-related quality of life: results from a nationwide 11-year follow-up study","volume":"28","author":"Taipale","year":"2019","journal-title":"Qual Life Res"},{"key":"2025090110051491000_6.1.e000896.22","unstructured":"Centers for Disease Control and Prevention . Vision loss: a public health problem, 2020. Available: https:\/\/www.cdc.gov\/visionhealth\/basic_information\/vision_loss.htm"},{"key":"2025090110051491000_6.1.e000896.23","doi-asserted-by":"crossref","first-page":"100852","DOI":"10.1016\/j.eclinm.2021.100852","article-title":"Global economic productivity losses from vision impairment and blindness","volume":"35","author":"Marques","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025090110051491000_6.1.e000896.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.11.017"},{"key":"2025090110051491000_6.1.e000896.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00659-0"},{"key":"2025090110051491000_6.1.e000896.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.023"},{"key":"2025090110051491000_6.1.e000896.27","unstructured":"Allergan . Highlights of prescribing information Ozurdex\u00ae (dexamethasone intravitreal implant) 2020:1\u201315."}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2021-000896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T17:05:26Z","timestamp":1756746326000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2021-000896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,11,10]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/bmjophth-2021-000896"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2021-000896","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}